<DOC>
	<DOCNO>NCT00000807</DOCNO>
	<brief_summary>To assess toxicity , tumor response rate , effect quality life daily low-dose etoposide administer 7 consecutive day every week patient AIDS-related Kaposi 's sarcoma relapse progressed systemic chemotherapy . Etoposide may least , even , effective less myelotoxic give low dos prolong period time .</brief_summary>
	<brief_title>Phase II Evaluation Low-Dose Oral Etoposide Treatment Relapsed Progressed AIDS-Related Kaposi 's Sarcoma After Systemic Chemotherapy</brief_title>
	<detailed_description>Etoposide may least , even , effective less myelotoxic give low dos prolong period time . Patients receive low-dose oral etoposide day 1 7 every 2-week cycle . Patients achieve complete partial response two cycle toxicity great grade 2 may dose escalated subsequent cycle . If response therapy among first 14 evaluable patient , study close ; least one objective response therapy among first 14 evaluable patient , enrollment continue 41 patient enrol . Patients continue therapy maximal tumor response ( either stable disease complete response ) achieve disease progression occur .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Maintenance therapy opportunistic infection . Patients must : HIV infection . Kaposi 's sarcoma relapse progress . Mucocutaneous lesion ( 15 ) and/or symptomatic mucosal lesion and/or visceral Kaposi 's sarcoma ( symptomatic lymphedema qualifies patient absence three condition ) . NO active acute opportunistic infection require treatment myelosuppressive antibiotic ( maintenance OIs permit ) . Consent parent guardian le 18 year age . NOTE : This study approve prisoner participation . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Other active malignancy except basal cell carcinoma skin , carcinoma situ cervix . Grade 3 bad peripheral neuropathy . Altered mental status would prevent informed consent prevent study compliance . Patients follow prior condition exclude : Neuropsychiatric history . Prior Medication : Excluded : Prior etoposide . Any antiKS drug within 14 day prior study entry . Any investigational drug antiretrovirals within 14 day prior study entry . Any prior investigational agent , give ONLY prior treatment KS . Prior Treatment : Excluded : Radiation therapy within 7 day prior study entry . Continued alcohol consumption continue intravenous drug use would impair ability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>